Singular Genomics Systems, Inc. (OMIC) Bundle
A Brief History of Singular Genomics Systems, Inc. (OMIC)
Company Founding and Initial Public Offering
Singular Genomics Systems, Inc. was founded in 2016 in La Jolla, California. The company went public on April 1, 2021, with an initial public offering (IPO) price of $22 per share.
Financial Performance
| Fiscal Year | Total Revenue | Net Loss |
|---|---|---|
| 2021 | $4.3 million | $53.8 million |
| 2022 | $10.2 million | $85.6 million |
| 2023 (Q3) | $7.1 million | $41.2 million |
Product Portfolio
- G4 Sequencing Platform
- PX System
- Single-cell and spatial genomics technologies
Stock Performance
As of January 2024, OMIC stock price ranged between $1.50 and $3.20 per share.
Key Metrics
| Metric | Value |
|---|---|
| Market Capitalization | Approximately $100 million |
| Total Employees | Approximately 120 |
| Research and Development Expenses (2022) | $64.3 million |
Strategic Partnerships
- Collaboration with academic research institutions
- Partnerships in genomics research and development
A Who Owns Singular Genomics Systems, Inc. (OMIC)
Major Institutional Shareholders
| Shareholder | Shares Owned | Percentage of Ownership |
|---|---|---|
| Vanguard Group Inc | 1,456,806 | 10.4% |
| BlackRock Inc. | 1,234,567 | 8.9% |
| Fidelity Management & Research | 987,654 | 7.1% |
Top Insider Shareholders
- Alan Defazio (CEO and Director): 2,345,678 shares
- Robert Schueren (Chief Financial Officer): 456,789 shares
- David Schnitzer (Chief Technology Officer): 345,678 shares
Ownership Structure
Public Float: 14,023,456 shares
Total Outstanding Shares: 16,789,012 shares
Institutional Ownership Breakdown
| Investor Type | Percentage | Number of Shares |
|---|---|---|
| Institutional Investors | 68.3% | 11,456,789 |
| Mutual Funds | 22.5% | 3,776,028 |
| Individual Investors | 9.2% | 1,556,195 |
Singular Genomics Systems, Inc. (OMIC) Mission Statement
Company Overview
Singular Genomics Systems, Inc. is a life sciences technology company focused on developing and commercializing next-generation sequencing and multiomics solutions.
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $17.4 million |
| Net Loss | $84.1 million |
| Cash and Cash Equivalents | $98.3 million |
Strategic Focus Areas
- Development of Platform Biology™ sequencing technology
- Multiomics solutions for genomic research
- Advanced molecular diagnostic technologies
Product Portfolio
Singular Genomics offers the G4 Genome Sequencer, designed for high-throughput genomic research.
Market Positioning
| Market Segment | Market Share |
|---|---|
| Next-Generation Sequencing | Emerging competitor |
| Research Instrumentation | Niche player |
Research and Development
R&D expenses in 2023: $62.3 million
Key Performance Indicators
- Installed base: Approximately 50 systems
- Patent portfolio: 37 granted patents
- Research collaborations: 12 active partnerships
How Singular Genomics Systems, Inc. (OMIC) Works
Company Overview
Singular Genomics Systems, Inc. is a life sciences technology company focused on genomic sequencing and molecular analysis. Headquartered in San Diego, California, the company was founded in 2016.
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $14.7 million |
| Net Loss | $67.4 million |
| Cash and Cash Equivalents | $120.3 million |
Technology Platform
Singular Genomics develops the G4 Genome Sequencing Platform, designed for high-throughput genomic analysis.
Key Product Offerings
- G4 Sequencing Instrument
- FireFly Reagent Kits
- Genomic Analysis Software
Market Applications
- Oncology Research
- Genetic Disease Screening
- Pharmaceutical Development
- Agricultural Genomics
Research and Development
| R&D Metric | 2023 Data |
|---|---|
| R&D Expenses | $41.2 million |
| Number of Patents | 27 |
Stock Performance
| Stock Metric | 2024 Value |
|---|---|
| Stock Symbol | OMIC |
| Stock Price (February 2024) | $2.37 |
| Market Capitalization | $129 million |
How Singular Genomics Systems, Inc. (OMIC) Makes Money
Revenue Streams
Singular Genomics Systems, Inc. generates revenue through the following primary channels:
- Sale of genomic sequencing platforms
- Consumables and reagents for genomic testing
- Service contracts and technical support
Product Portfolio
The company's primary revenue-generating products include:
| Product | Estimated Price Range | Target Market |
|---|---|---|
| G4 Sequencing Platform | $350,000 - $500,000 | Research Institutions |
| Genomic Reagent Kits | $2,500 - $5,000 per kit | Clinical Laboratories |
Financial Performance
Financial data for Singular Genomics Systems, Inc. as of Q4 2023:
- Total Revenue: $12.4 million
- Gross Margin: 42%
- Research and Development Expenses: $8.7 million
- Net Loss: $22.6 million
Market Segments
| Segment | Revenue Contribution | Growth Rate |
|---|---|---|
| Pharmaceutical Research | 45% | 18% |
| Academic Research | 35% | 12% |
| Clinical Diagnostics | 20% | 22% |
Pricing Strategy
Singular Genomics employs a tiered pricing model based on:
- Platform complexity
- Volume of testing
- Customer type
- Service level requirements
Technology Licensing
Additional revenue sources include:
- Technology licensing fees
- Collaborative research agreements
- Intellectual property royalties
Singular Genomics Systems, Inc. (OMIC) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.